Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.98 |
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.80 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.80 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.80 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.80 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.80 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.80 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.80 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.98 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.98 |
| ▸ | MC4R | P32245 | 1/20 | 0.98 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | ABL1 | P00519 | 2/20 | 0.80 |
| ▸ | HTR1A | P08908 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.80 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL18496409 | 0.99 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL29919725 | 0.99 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL15939735 | 0.99 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL162935 | 0.99 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL28204502 | 0.98 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL16051185 | 0.96 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3664023 | 0.96 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Cm-4307 SCHEMBL14673524 | 0.94 | KDR (0.90) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL19322 | 0.92 | KDR (0.87) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18264082 | 0.92 | KDR (0.86) | KDRAURKBNTSR1MC4RPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019155486-A1 | PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE POLYMORPH III | NATCO PHARMA LIMITED (IN) | 2019-08-15 | — | — | WO | claimed |
| US-8217061-B2 | crystalline Sorafenib tosylate | SICOR INC. (US) | 2012-07-10 | — | — | US | claimed |
| EP-2231612-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | Sicor, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090192200-A1 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. | 2009-07-30 | — | — | US | claimed |
| WO-2009092070-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. (US) | 2009-07-23 | — | — | WO | claimed |
| CN-111704574-B | Preparation method of high-purity sorafenib tosylate crystal form III | 齐鲁制药有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-107840823-B | Variable-scale process for preparing sorafenib tosylate ethanol solvate and sorafenib tosylate form III | 意大利合成制造有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-108164459-B | Preparation method of sorafenib tosylate crystal form III | 上海创诺制药有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-108164459-B | Preparation method of sorafenib tosylate crystal form III | 上海创诺制药有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-2852574-B1 | PROCESS FOR SORAFENIB TOSYLATE POLYMORPH III | HETERO RESEARCH FOUNDATION (IN) | 2020-02-05 | — | — | EP | disclosed |
| CN-108210468-B | A kind of preparation method of Sorafenib Tosylate oral administration nanometer preparation | BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY (CN) | 2019-10-29 | — | — | CN | disclosed |
| CN-110339173-A | A kind of Sorafenib Tosylate nanometer tablet | 北京化工大学 | 2019-10-18 | — | — | CN | disclosed |
| WO-2014118807-A1 | A NOVEL PROCESS FOR THE PREPARATION OF SORAFENIB TOSYLATE FORM III | INTAS PHARMACEUTICALS LIMITED (IN) | 2014-08-07 | — | — | WO | disclosed |
| WO-2013175506-A2 | PROCESS FOR SORAFENIB TOSYLATE POLYMORPH III | HETERO RESEARCH FOUNDATION (IN) | 2013-11-28 | — | — | WO | disclosed |
| US-8217061-B2 | crystalline Sorafenib tosylate | SICOR INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2231612-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | Sicor, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231612-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | Sicor, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192200-A1 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009092070-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009092070-A1 | POLYMORPH FORM III OF SORAFENIB TOSYLATE, SORAFENIB TOSYLATE METHANOL SOLVATE AND SORAFENIB TOSYLATE ETHANOL SOLVATE, AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192200-A1 | POLYMORPHS OF SORAFENIB TOSYLATE AND SORAFENIB HEMI-TOSYLATE, AND PROCESSES FOR PREPARATION THEREOF | BRAF, GYS2, HCCS | KDR 11/4885RAF1 49/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.